STOCK TITAN

Ra Medical Systems Announce Issuance of Additional International Patent

Rhea-AI Impact
(Moderate)
Rhea-AI Sentiment
(Neutral)
Tags

FORT MILL, SC / ACCESSWIRE / March 17, 2023 / Ra Medical Systems, Inc. (RMED:NYSE/American) today announced that its wholly owned subsidiary, Catheter Precision, Inc., has received notification of an additional issuance of a new international patent. The patent is part of the evolving number of patents surrounding the company's VIVO technology. The patent, entitled "Methods of Cardiac Mapping and Model Merging" has been issued in the country of Japan.

RMED's Executive Chairman, David Jenkins, commented. "As a medical device company, we realize that intellectual property is a key part of growing not only our value but also our market presence. We are pleased that our technology in the field of cardiac electrophysiology continues to be recognized as unique and different. This patent combines with our entire estate of over fifty patents and patent applications covering our different product areas."

About VIVO

Catheter Precision's VIVO™ (View Into Ventricular Onset), is a non-invasive 3D imaging system that enables physicians to identify the origin of ventricular arrhythmias pre-procedure, thereby streamlining workflow and reducing procedure time. VIVO has received marketing clearance from the U.S. FDA and has the CE mark.

About Ra Medical Systems

Ra Medical, and its wholly owned subsidiary Catheter Precision, is an innovative U.S.-based medical device company bringing new solutions to market to improve the treatment of cardiac arrhythmias. It is focused on developing groundbreaking technology for electrophysiology procedures by collaborating with physicians and continuously advancing its products.

CONTACTS:

At the Company
David Jenkins
973-691-2000
mhuck@catheterprecision.com

SOURCE: Ra Medical Systems, Inc.



View source version on accesswire.com:
https://www.accesswire.com/744254/Ra-Medical-Systems-Announce-Issuance-of-Additional-International-Patent

Ra Medical Systems, Inc.

NYSE:RMED

RMED Rankings

RMED Latest News

RMED Stock Data

3.84M
4.60M
36.85%
11%
1.26%
Surgical and Medical Instrument Manufacturing
Manufacturing
Link
US
Carlsbad

About RMED

advanced excimer laser-based vascular and dermatological therapies we are a commercial-stage medical device company leveraging our advanced excimer laser-based platform for use in the treatment of vascular and dermatological diseases. we believe our products enhance patients’ quality of life by restoring blood-flow in arteries and clearing chronic skin conditions. we currently manufacture and market two lines of products: dabra catheter and laser is cleared by the u.s. fda as a tool for the minimally invasive endovascular treatment of vascular blockages resulting from lower extremity vascular disease, which includes peripheral artery disease (pad), which commonly occurs in the legs. pharos excimer laser pharos is designed for use in the treatment of inflammatory skin conditions and is fda cleared as a tool used in the treatment of psoriasis, atopic dermatitis, and leukoderma. our goal is to become the leading medical device company marketing excimer lasers as tools for the treatment of